title: Infections associated with totally implantable venous access devices (TIVAD) in human immunodeficiency virus-infected patients.
abstract: We report on a retrospective study evaluating infectious morbidity associated with totally implantable venous access devices (TIVAD) (Port-A-Cath) in HIV-infected patients. This study of 84 consecutive HIV-infected patients requiring 89 TIVAD between January 1990 and October 1993 was performed in the Department of Infectious Diseases Hôpital de l'Institut Pasteur, Paris, France. The total number of catheter days was 11,595. Eighteen of 89 patients with TIVAD (20%) were infected, causing 25 infectious events (25/89: 28%) among 17 different patients (17/84: 20%). The infection rate was 0.22 per 100 catheter days. Mean onset of infection was 82 days. Twenty microorganisms were isolated: Staphylococcus aureus in eight cases (40%), coagulase-negative Staphylococcus in six cases (30%), Streptococcus D faecalis in one case; Gram-negative bacilli were found in five cases (25%). All patients received an intravenous antibiotherapy combined with a local lock treatment in eight cases. Nine TIVAD removals were performed. One death was related to the TIVAD infection. No additional predisposing factor for infection was identified other than the implied condition of the HIV infection. The population and material in this study were homogeneous. The TIVAD infection rate was comparable to other published reports. Prospective evaluation comparing tunneled catheter and TIVAD in HIV-infected patients is needed.
authors.affiliation: Department of Infectious Diseases, Hôpital de l'Institut Pasteur, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Dega
authors.forename: M
authors.initials: M
authors.lastname: Eliaszewicz
authors.forename: M
authors.initials: M
authors.lastname: Gisselbrecht
authors.forename: J
authors.initials: J
authors.lastname: Fleury
authors.forename: G
authors.initials: G
authors.lastname: Pialoux
authors.forename: B
authors.initials: B
authors.lastname: Janssen
authors.forename: L
authors.initials: L
authors.lastname: de Saint-Martin
authors.forename: G
authors.initials: G
authors.lastname: Gonzalez-Canali
authors.forename: B
authors.initials: B
authors.lastname: Dupont
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents